Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial

INTRODUCTION: Subcutaneous emicizumab prophylaxis substantially reduces bleeding episodes in patients with haemophilia A (PwHA) and factor VIII inhibitor. However, thrombotic events occurred in some PwHA with inhibitor who had received high cumulative doses of activated prothrombin complex concentra...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogiwara, Kenichi, Taki, Masashi, Suzuki, Takashi, Takedani, Hideyuki, Matsushita, Tadashi, Amano, Kagehiro, Matsumoto, Masanori, Nishio, Kenji, Shima, Midori, Kasahara, Masato, Nogami, Keiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860020/
https://www.ncbi.nlm.nih.gov/pubmed/35177463
http://dx.doi.org/10.1136/bmjopen-2021-056922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860020/
https://www.ncbi.nlm.nih.gov/pubmed/35177463
http://dx.doi.org/10.1136/bmjopen-2021-056922

Ejemplares similares